Want to see ABCL full AI Analyst Report?
Top Page
AbCellera Biologics
(NASDAQ:ABCL)
Select Model
Select Model
Rating:53Neutral
Price Target:
$8.00
▲(99.50% Upside)
Action:Reiterated
Date:07/07/26
The score is held back primarily by weak financial performance (large losses and negative free cash flow despite good margins and low leverage). Technicals are constructive with strong trend signals, but momentum indicators are stretched, increasing pullback risk. The earnings call and recent partnership/news flow are positive due to clear clinical catalysts and strong liquidity, while valuation remains constrained by unprofitability (negative P/E).
Positive Factors
Integrated discovery platform & strategic collaboration
A sizable Jazz collaboration validates AbCellera’s integrated discovery-to-development platform, provides meaningful non-dilutive upfront funding and large milestone/royalty potential, and expands the company’s addressable oncology opportunity—structural support for recurring partner-driven R&D revenue and long-term platform monetization.
Negative Factors
Negative operating cash flow
Sustained negative operating and free cash flow means the business cannot self-fund growth today and must rely on balance sheet liquidity, partnerships, or capital markets. If clinical or partnership milestones slip, continued cash burn will pressure runway and could force dilution or cutbacks, limiting strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated discovery platform & strategic collaboration
A sizable Jazz collaboration validates AbCellera’s integrated discovery-to-development platform, provides meaningful non-dilutive upfront funding and large milestone/royalty potential, and expands the company’s addressable oncology opportunity—structural support for recurring partner-driven R&D revenue and long-term platform monetization.
Read all positive factors
AbCellera Biologics Key Performance Indicators (KPIs)
Any
Number of Discovery Partners
Indicates the breadth of AbCellera's collaborative network, highlighting potential for diverse innovation and revenue streams through partnerships.
Indicates the breadth of AbCellera's collaborative network, highlighting potential for diverse innovation and revenue streams through partnerships.
Data provided by:
The Fly
The FlyAbCellera Biologics (ABCL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.48B
Dividend YieldN/A
Average Volume (3M)7.90M
Price to Earnings (P/E)―
Beta (1Y)1.76
Revenue Growth242.66%
EPS Growth15.53%
CountryUS
Employees596
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.48
Shares Outstanding305,375,400
10 Day Avg. Volume4,997,009
30 Day Avg. Volume7,898,538
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)1.06
Price to Sales (P/S)13.60
P/FCF Ratio-5.87
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue21.77
Enterprise Value/Gross Profit27.53
Enterprise Value/Ebitda-10.94
Forecast
1Y Price Target
$9.40Price Target Upside134.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.59
Revenue Forecast (FY)$33.21M
AbCellera Biologics Business Overview & Revenue Model
Company Description
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creatio...
How the Company Makes Money
AbCellera primarily makes money by partnering with pharmaceutical and biotechnology companies to discover and develop therapeutic antibodies. Its revenue model typically includes (1) research fees and reimbursements for antibody discovery and rela...
AbCellera Biologics Earnings Call Summary
Earnings Call Date:May 11, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call conveyed a generally positive clinical and financial picture: compelling interim Phase I data for ABCL635 (favorable tolerability, strong PK/PD and sustained target engagement) with a clear near-term Phase II catalyst (Q3 2026), expanding pipeline progress, and a robust liquidity position (~$655M available including government funding). Headwinds include continued quarterly losses (~$43M), modest current revenue (~$8M) with expected declines in partner-derived research fees, a small potential tolerability signal at the highest dose (900 mg), blinded MAD data limiting full visibility, and remaining scientific/efficacy risk until Phase II readout. Overall, positives (clinical momentum, liquidity, and pipeline cadence) outweigh the negatives, but the company remains dependent on upcoming Phase II and other near-term milestones.Positive Updates
Promising ABCL635 Phase I Interim Data
Unblinded single-ascending-dose data show ABCL635 was generally well tolerated with no serious adverse events, no severe adverse events, no discontinuations and no liver toxicity; overall incidence of any adverse event was 50% in both treatment and pooled placebo groups with the vast majority grade 1.
Negative Updates
Ongoing Net Loss
Net loss for Q1 2026 was roughly $43M (loss per share $0.14) versus a loss of about $46M a year earlier — an improvement but still a significant quarterly loss (≈6.5% reduction in net loss year-over-year).
Read all updates
Q1-2026 Updates
Positive
Negative
Promising ABCL635 Phase I Interim Data
Unblinded single-ascending-dose data show ABCL635 was generally well tolerated with no serious adverse events, no severe adverse events, no discontinuations and no liver toxicity; overall incidence of any adverse event was 50% in both treatment and pooled placebo groups with the vast majority grade 1.
Read all positive updates
Company Guidance
AbCellera's guidance focused on near‑term clinical and financial milestones: a topline Phase II readout for ABCL635 is expected in Q3 2026 and a topline Phase I readout for ABCL575 in Q4 2026, with plans to add at least one new development candidate and select a fifth candidate in H1 2026 and to have up to three additional clinical‑stage programs (including ABCL688 and ABCL386) by end of 2027; commercially, the company said it will prioritize internal programs (research fee revenue expected to trend lower) while remaining well‑funded with approximately $531 million in cash, cash equivalents and marketable securities (including ~$428 million in short‑term securities), roughly $125 million of committed government funding (bringing total available liquidity to about $655 million), Q1 revenue of ~$8 million (vs ~$4M a year earlier), R&D spend of ~ $47 million, SG&A of ~ $12 million (down >35% from ~$19M), an operating cash use of ~$34 million (or ~$3M excluding investments), a net loss of ~ $43 million (loss per share ~$0.14), and the assertion that this runway and secured funding should support at least the next three years of pipeline investment.AbCellera Biologics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
63
Positive
Cash Flow
31
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 79.21M | 75.13M | 28.83M | 38.02M | 485.42M | 375.20M |
| Gross Profit | 62.63M | 46.31M | 28.83M | 38.02M | 418.99M | 329.69M |
| EBITDA | -157.61M | -148.77M | -204.15M | -192.16M | 260.17M | 239.15M |
| Net Income | -143.96M | -146.41M | -162.86M | -146.40M | 158.52M | 153.46M |
Balance Sheet | ||||||
| Total Assets | 1.31B | 1.36B | 1.36B | 1.49B | 1.54B | 1.32B |
| Cash, Cash Equivalents and Short-Term Investments | 504.73M | 533.83M | 625.61M | 760.59M | 886.49M | 722.98M |
| Total Debt | 140.18M | 143.22M | 65.36M | 77.38M | 82.26M | 40.06M |
| Total Liabilities | 369.03M | 390.05M | 304.47M | 335.78M | 307.63M | 292.84M |
| Stockholders Equity | 938.08M | 966.90M | 1.06B | 1.15B | 1.23B | 1.03B |
Cash Flow | ||||||
| Free Cash Flow | -189.23M | -174.07M | -186.95M | -121.38M | 204.70M | 186.13M |
| Operating Cash Flow | -153.26M | -131.29M | -108.56M | -43.88M | 277.36M | 244.58M |
| Investing Cash Flow | 54.73M | 87.75M | 121.41M | -221.11M | -352.63M | -332.25M |
| Financing Cash Flow | 15.30M | 14.08M | 12.77M | 10.36M | -1.63M | -3.89M |
AbCellera Biologics Technical Analysis
Positive
4.01
Price Trends
5.43
Positive
4.45
Positive
4.40
Positive
Market Momentum
0.74
Negative
68.56
Neutral
81.44
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABCL, the sentiment is Positive. The current price of 4.01 is below the 20-day moving average (MA) of 6.21, below the 50-day MA of 5.43, and below the 200-day MA of 4.40, indicating a bullish trend. The MACD of 0.74 indicates Negative momentum. The RSI at 68.56 is Neutral, neither overbought nor oversold. The STOCH value of 81.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABCL.
AbCellera Biologics Risk Analysis
AbCellera Biologics disclosed 99 risk factors in its most recent earnings report. AbCellera Biologics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AbCellera Biologics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $4.26B | -24.40 | -32.55% | ― | ― | -7.28% | |
56 Neutral | $3.81B | -9.47 | -68.97% | ― | 67.38% | 24.05% | |
56 Neutral | $3.80B | -20.74 | -15.14% | ― | ― | -4.45% | |
55 Neutral | $5.16B | -395.95 | -1.78% | ― | -79.52% | -43.40% | |
53 Neutral | $2.48B | -16.40 | -14.86% | ― | 242.66% | 15.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $1.93B | -7.89 | -256.66% | ― | 397.28% | 27.68% |
* Healthcare Sector Average
ABCL
AbCellera Biologics
7.87
3.84
95.29%
SNDX
Syndax Pharmaceuticals
22.08
13.35
152.92%
RCUS
Arcus Biosciences
29.98
21.76
264.72%
DNTH
Dianthus Therapeutics
93.34
75.09
411.45%
EWTX
Edgewise Therapeutics
40.10
27.49
218.00%
GPCR
Structure Therapeutics, Inc. Sponsored ADR
54.75
36.02
192.31%
AbCellera Biologics Corporate Events
Business Operations and StrategyExecutive/Board Changes
AbCellera Biologics Adds Independent Director to Board
Positive
Jul 6, 2026
On June 30, 2026, AbCellera Biologics Inc. appointed Lynn Seely, M.D., as an independent Class III director to its Board, with her term running until the 2029 annual meeting of shareholders. The Board determined she meets Nasdaq independence stand...
Business Operations and Strategy
AbCellera, Jazz Partner on Next-Generation Cancer Antibodies
Positive
Jun 17, 2026
On June 17, 2026, Jazz Pharmaceuticals and AbCellera Biologics announced a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging multispecific antibodies for multiple gastrointesti...
Executive/Board ChangesShareholder Meetings
AbCellera Shareholders Back Directors, Auditors, Executive Pay
Positive
Jun 12, 2026
AbCellera Biologics Inc. held its Annual Meeting of Shareholders on June 11, 2026, with 305,264,947 common shares eligible to vote as of the April 15, 2026 record date. Shareholders approved the election of Class III directors John S. Montalbano a...
Business Operations and StrategyExecutive/Board Changes
AbCellera Biologics Adds Victor Sandor to Board
Positive
Jun 5, 2026
On June 1, 2026, AbCellera Biologics appointed medical oncologist Victor Sandor to its board of directors as an independent director, with his term running until the next annual shareholders’ meeting. The Nasdaq-listed company said Sandor wi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.